PharmacoEconomics & Outcomes News 804, p26 - 2 Jun 2018 Pertussis cost reduction through vaccination in Spain Children, aged 0–9 years with pertussis, have reduced mean direct healthcare costs following vaccination with 4–5 doses of acellular vaccines than their unvaccinated or partially vaccinated peer group, according to the findings of a study conducted in Catalonia (Spain). All children aged 0–9 years in Catalonia with pertussis detected by epidemiological surveillance between 1 January 2012 and 31 December 2013, and with validated vaccination status were included in the study (n = 579). Direct health costs comprising the expenditure for detection, treatment and chemoprophylaxis of contacts were calculated. Participants were classified as vaccinated (4–5 doses (45.3%)), partially vaccinated (1–3 doses (27.5%)) or unvaccinated (27.3%). The odds ratios were significantly lower in the vaccinated cohort for hospitalisation (OR 0.02, p < 0.001), severe disease (OR 0.02, p < 0.001) and laboratory based pertussis confirmation (OR 0.21, p < 0.001) than the unvaccinated or partially vaccinated children. Mean direct healthcare costs (based on resources used and prices in 2012–2013) were significantly lower (p < 0.001) in vaccinated patients than partially or unvaccinated patients at €190.6 (6.3% of total pertussis costs), €1116.9 (22.5%) and €3550.8 (71.2%) respectively. Multivariable linear regression analysis revealed that 4–5 doses of pertussis vaccine was associated with a non-significant reduction of €107.9/case after accounting for other study variables and €200/case after accounting for disease severity. "The results obtained in this study indicate that pertussis vaccination during childhood is one of the key pertussis prevention strategies to reduce the burden of pertussis and pertussis costs in individuals aged 0–9 years", concluded the authors. Plans-Rubio P, et al. Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain). PharmacoEconomics-Open : 14 May 2018. Available from: URL: https://doi.org/10.1007/s41669-018-0081-4 803322890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera